Minal Patel

The test was real. The need for it was not.

Minal Patel, owner of a genetic testing laboratory called LabSolutions LLC in Atlanta, Georgia, built a business model around manufactured demand. The genetic tests his laboratory performed were legitimate medical procedures. The question they were intended to answer — does this patient have a genetic predisposition to a condition, and does this affect their medication options — is a real clinical question. But the patients who received those tests under Patel's scheme, per the DOJ, were not patients whose doctors had determined they needed genetic testing. They were people whose details had been obtained by marketers who were paid for every test they brought in.

The kickback structure: Patel's laboratory paid marketers a fee per test — not a per-referral fee that a physician might receive, but a per-unit payment to salespeople whose job was to generate test orders from elderly and vulnerable people, often by using their Medicare or insurance information without the patients' full understanding. Some patients did not know a test had been ordered in their name. Some were told they were receiving a service they had not requested. [SOURCE: DOJ]

~$463 million was billed to Medicare and private insurers. ~$187 million was paid. The difference is the portion that was refused, reversed, or detected. Patel was convicted by a jury in December 2022 and sentenced in August 2023 to 27 years in federal prison — one of the longest sentences in the history of healthcare fraud prosecutions. He personally received more than $21 million. [SOURCE: DOJ, August 2023]

The conventional healthcare fraud case involves a false claim — a service that was not provided, billed as if it were. Patel's case is the complement: a service that was provided, but should not have been, because the patient had no genuine need for it and the need was invented by a payment structure.

Genetic testing is expensive and covered by Medicare when medically indicated — when a physician, based on clinical judgment, determines that the test result would affect the patient's treatment. The kickback network Patel operated bypassed that clinical judgment entirely. Marketers recruited elderly patients — mostly through telemarketing calls that falsely said Medicare covered the tests, with telemedicine doctors signing the orders, and senior communities — and generated test orders associated with their identities, sometimes without the patients' knowledge or meaningful consent.

This is manufactured demand: the creation of apparent need through financial incentives paid to people whose interest is the kickback, not the patient's clinical outcome. The test results, once generated, provided cover for the billing claim. The patient exists; the test was performed; the claim is technically defensible. The fraud is in the kickback that generated the order in the first place.

The victims include people who were tested without genuine need and whose insurance details were used without full consent. They were targeted because they were elderly and because Medicare coverage made the billing easy. [SOURCE: DOJ]

Three healthcare cases in this series; Patel is the second. Perez (043) used a billing licence to fabricate claims. Patel used a kickback network to manufacture demand. Esformes (045) used kickbacks to purchase patient referrals into a nursing-home network.

The 27-year sentence distinguishes Patel's case from the others in the healthcare category. It reflects the specific harm documented — the targeting of vulnerable patients, the sustained operation of the kickback network, and the scale of the billing. It is one of the longest sentences in US healthcare fraud history as of its imposition in 2023. State it factually; do not editorialize about proportionality.